Australia vs South-Eastern Asia: Proportion of the target population who received a 3rd dose of
Australia
95.0%
in 2024
South-Eastern Asia
56.0%
in 2024
Australia rank
28th
South-Eastern Asia rank
28th
Proportion of the target population who received a 3rd dose of over time
- Australia
- South-Eastern Asia
How they compare
Australia currently reports 95.0% against 56.0% in South-Eastern Asia, a difference of 39.0%.
That makes Australia's figure about 1.7 times South-Eastern Asia's.
Across all 16 years both countries report, Australia has been ahead every year.
Australia ranks 28th and South-Eastern Asia ranks 28th of 157 countries.
Australia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Australia | South-Eastern Asia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 91.0% | 0.0% | 91.0% | Australia |
| 2010s | 92.7% | 9.5% | 83.2% | Australia |
| 2020s | 95.8% | 35.6% | 60.2% | Australia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher proportion of the target population who received a 3rd dose of, Australia or South-Eastern Asia?
- Australia, at 95.0% against 56.0% in South-Eastern Asia as of 2024.
- What is the difference in proportion of the target population who received a 3rd dose of between Australia and South-Eastern Asia?
- 39.0%, with Australia ahead.
- How many years of comparable data are there for Australia and South-Eastern Asia?
- 16 years are reported by both, from 2009 to 2024.
- How do Australia and South-Eastern Asia rank globally for proportion of the target population who received a 3rd dose of?
- Australia ranks 28th and South-Eastern Asia ranks 28th of 157 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Proportion of the target population who received a 3rd dose of pneumococcal conjugate (PCV3) vaccine (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.